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OBJECTIVES The purpose of this study was to analyze the feasibility, efficacy, and safety of epicardial
radiofrequency (RF) ablation in patients with incessant ventricular tachycardia (VT).
BACKGROUND Management of patients with incessant VT is a difficult clinical problem. Drugs and RF
catheter ablation are not always effective. A nonsurgical transthoracic epicardial RF ablation
can be an alternative in patients refractory to conventional therapy.
METHODS Epicardial RF ablation was performed in 10 patients who presented with incessant VT
despite the use of two or more intravenous antiarrhythmic drugs.
RESULTS In eight patients, endocardial ablation (EdA) failed to control the tachycardia. In the
remaining two patients, epicardial ablation (EpA) was first attempted because of left
ventricular thrombus and severe artery disease, respectively. Eight patients had a diagnosis of
coronary artery disease with healed myocardial infarction. One patient had dilated cardio-
myopathy, and one patient had idiopathic, incessant VT. In patients with structural heart
disease, the mean ejection fraction was 0.28  0.10%. Four patients previously received an
implantable defibrillator. The EpA effectively terminated the incessant tachycardia in eight
patients, which represents a success rate of 80%. In them, after a follow-up of 18  18
months, a single episode of a different VT was documented in one patient. No significant
complications occurred related to the procedure.
CONCLUSIONS In patients with incessant VT despite the use of drugs or standard EdA, the epicardial
approach was very effective and should be considered as an alternative in this life-threatening
situation. (J Am Coll Cardiol 2003;41:2036–43) © 2003 by the American College of
Cardiology Foundation
Patients with incessant ventricular tachycardia (VT) repre-
sent a life-threatening situation, with great morbidity and
mortality, and often a difficult clinical problem. Radiofre-
quency (RF) catheter ablation is the therapy of choice when
intravenous drugs have failed. However, endocardial abla-
tion (EdA) of VT due to a previous myocardial infarction
(MI) or in patients with structural heart disease continues to
be one of the most challenging procedures in clinical
electrophysiology, with a success rate ranging from 45% to
75% (1,2).
See page 2044
The reasons for unsuccessful EdA are often difficult to
ascertain. One reason thus far exposed is that the re-entry
circuits may be located deep in the subendocardium or in
the epicardium, inaccessible to present mapping and abla-
tion techniques (3,4). Mapping of arrhythmia foci or circuits
that are deep within the myocardium or in the epicardium
has been attempted in open-chest heart surgery (5,6) and
with RF ablation catheters in two ways. Small, 2F electrode
catheters have been introduced into the coronary sinus and
advanced into the cardiac veins. With this technique,
epicardial circuits can sometimes be identified, but only
when veins cross the region of the circuit (7). In 1996, Sosa
et al. (8–11) introduced a new transthoracic epicardial
method for the electrophysiologic study of patients with VT
and, two years later, for the ablation of the arrhythmia. The
method is based on the hypothesis that some crucial parts of
the re-entry circuit in VT might be located near the
epicardial site of the ventricle. The technique is performed
by introducing a standard ablation catheter into the peri-
cardial space, using a transthoracic puncture in the subxi-
phoid region. The new technique was first described in
patients with Chagas’ disease (8–10). More recently, they
have also shown their experience in a group of patients with
an inferiorly healed MI with preserved left ventricular
function (11).
In patients with incessant VT in whom the classic EdA
procedure has failed, the epicardial approach can be an
alternative. The aim of this study was to analyze the efficacy
and safety of epicardial ablation (EpA) in patients with
incessant VT.
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METHODS
Study patients. Since 1998, ablation was attempted in 150
patients with VT. Epicardial ablation was performed in 10
of 19 patients with incessant VT. We considered VT to be
incessant when, despite the use of at least two intravenous
antiarrhythmic drugs, electrical cadioversion, and/or over-
drive stimulation, the patient presented with persistent,
recurrent, sustained VT for at least a 24-h period.
In eight patients, the usual endocardial approach had
failed to terminate VT, despite the use of standard and
special catheters (8-mm tip in five patients and endocardial
irrigated tip in three patients). In the remaining two
patients, the endocardial approach was not tried because of
the presence of a left ventricular thrombus and severe
arterial disease, respectively.
No patient was excluded from ablation on the basis of
infarct location, left ventricular function, presence or ab-
sence of an aneurysm, number of ventricular configurations,
or characteristics of VT.
In the whole group, a coronary artery and left ventricular
angiogram was obtained before the procedure. Analysis of
the angiogram was used to establish the proximity between
the catheter tip and a coronary vessel before ablation.
Echocardiography was performed immediately after the
procedure and before hospital discharge. Likewise, we
monitored creatine kinase and its MB fraction during the
first 36 h after EpA.
All patients signed informed consent, approved by the
local ethics committee, to participate in the study.
Technique. After written, informed consent was obtained,
the patient was taken to the electrophysiology laboratory in
a fasting state and was mildly sedated with 10 mg diazepam.
During the procedure, intravenous fentanyl was given to
prevent pain during the applications or earlier if needed.
The technique used was the same as already described (8).
After asepsis of the subxiphoid region, local anesthesia was
attained with 10 ml of 2% mepivacaine. An epidural needle
was used for the pericardial puncture (Perican, 18G  31⁄4;
effective size 1.3  80 mm; Braun, Melsungen, Germany)
(12). Using a 10-ml syringe with contrast media (Omnitrast
350, Schering, Berlin, Germany), the needle was advanced
toward the left scapula, guided by fluoroscopy. When the
pericardial space was thought to be reached, a small bolus of
1 ml of contrast agent was injected. If the tip of the needle
was outside the pericardial space, a contrast bottom was
seen. When the tip was inside the pericardial space, the
cardiac silhouette was drawn (Fig. 1). A soft, floppy tipped
guidewire was then introduced into the pericardial space
while it was seen easily moving inside the pericardial sac.
The same 7F sheath used for standard ablation was then
advanced over the guidewire. A quadripolar, deflectable,
4-mm (n  7) or 8-mm (n  3) tipped catheter with
Figure 1. Radioscopic anteroposterior view showing a quadripolar diag-
nostic catheter in the right ventricle and an 8-mm tip ablation catheter in
the pericardial space. Note the contrast in the pericardial sac.
Figure 2. Radioscopic anteroposterior view showing an 8-mm tip ablation
catheter in the left ventricle and a 4-mm tip ablation catheter in the
pericardial space at the site of failed endocardial ablation and successful
epicardial ablation.
Abbreviations and Acronyms
CAD  coronary artery disease
ECG  electrocardiogram
EdA  endocardial ablation
EpA  epicardial ablation
LBBB  left bundle branch block
MI  myocardial infarction
RF  radiofrequency
SVT  supraventricular tachycardia
VT  ventricular tachycardia
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temperature control (Cordis-Webster Inc., Johnson &
Johnson, Diamond Bar, California) was introduced through
the sheath in the pericardial sac (Figs. 1 and 2).
The equipment used for recording was an EP-TRACER
(Cardio Tek bv, Maastricht, the Netherlands). The 12-lead
surface electrocardiogram (ECG), distal and proximal bipo-
lar electrograms of the EpA catheter, and endocardial
signals from a diagnostic catheter were displayed. The
stimulation protocol consisted of up to three extrastimuli
down to the refractory period or a coupling interval of 200
ms in sinus rhythm and at three different cycle lengths.
Selection of ablation site. Similar criteria to those used
during EdA were used to identify the site of VT origin in
the epicardium: earliest electrogram during tachycardia,
presence of mid-diastolic potentials or continuous diastolic
activity during tachycardia, entrainment mapping, and exact
pace mapping on the 12-lead ECG. Generally, the presence
of isolated mid-diastolic potentials was the first mapping
technique used. Potential target sites identified were evalu-
ated for entrainment mapping. Pace mapping was used if
presystolic activity was seen and VT was stopped. No other
cartographic system was used.
Radiofrequency pulses were applied between the tip of
the epicardial catheter and a patch electrode located behind
the left scapula (Stockert EP Shuttle, Cordis Webster Inc.).
Energy was delivered in all cases during VT. The temper-
ature limit was adjusted to 65° and power to 40 W. At the
chosen site, energy was applied for 20 s and, only if the VT
stopped, continued for up to 60 s. The clinical, incessant VT
was the target for ablation. In addition, other hemodynam-
ically stable VTs that occurred during the procedure were
targeted for ablation, as well. The ablation was considered
effective when VT terminated during the application and no
sustained VT could be induced.
Statistics. Continuous data are expressed as the mean value
 SD. Mean values were compared with the Student t test.
Statistical analyses were performed using the statistical
package SPSS version 10 for Windows (SPSS Inc., Chi-
cago, Illinois). A p value of 0.05 was considered signifi-
cant.
RESULTS
Radiofrequency epicardial catheter ablation was attempted
in 10 patients. The clinical characteristics are shown in
Table 1. The patients included nine men and one woman,
with a mean age of 68  9 years (range 55 to 78 years). All
patients were in New York Heart Association functional
class I or II before incessant VT. Eight patients (80%) had
coronary artery disease (CAD), with a previous MI in all of
them. One patient had been diagnosed with dilated cardio-
myopathy. Finally, the remaining patient had an idiopathic
VT. Myocardial infarction was located in the inferoposte-
rior wall in six cases and in the anterior wall in one case and
was unallocated in the remaining patient. The mean left
ventricular ejection fraction in the patients with structural
heart disease was 0.28 0.10% (range 0.15% to 0.46%) and
0.60% in the patient with idiopathic VT. At coronary
angiography, one-vessel disease was observed in three pa-
tients with total occlusion of the right, left anterior descend-
ing, and circumflex coronary arteries, respectively. One
patient had two-vessel disease and two patients had three-
vessel disease. Finally, four patients presented with nonsig-
nificant CAD. On angiography, four patients showed a
ventricular aneurysm.
A cardioverter-defibrillator was implanted in four pa-
tients before ablation therapy. The antiarrhythmic drugs
used before ablation were amiodarone (n  9), procain-
amide (n  8), lidocaine (n  3), sotalol (n  2), and
mexiletine (n  1). In ischemic patients, the interval
between MI and incessant VT presentation was a mean of
53  76 months (range 1 to 200 months). Due to incessant
VT, five patients had signs of heart failure decompensation.
Catheter mapping and ablation. The clinical VT had a
right bundle branch block pattern in eight patients (80%)
and a left bundle branch block (LBBB) pattern in two
patients (20%). The mean cycle length was 417  65 ms
(range 320 to 520 ms).
Eleven EpA sessions were performed in 10 patients. In
one patient, a second procedure was performed on the next
day, and no pericardial effusion nor adhesions were encoun-
Table 1. Clinical Characteristics of the Patients
Patient
No.
Gender
(M/F)
Age
(yrs)
FC
(NYHA) Cardiopathy
EF
(%)
MI
(Localization)
Endocardial
Attempt
VT
Morphology
Cycle
Length
(ms)
1 M 78 II Ischemic 20 Inferior Yes LBBB 405
2 F 77 I Ischemic 40 Inferior Yes LBBB 415
3 M 60 II Dilated 20 — Yes RBBB 380
4 M 74 II Ischemic 27 Anterior No RBBB 325
5 M 75 I Ischemic 30 Inferior Yes RBBB 480
6 M 55 II Ischemic 46 Inferior Yes RBBB 520
7 M 70 II Ischemic 15 Posterolateral Yes RBBB 480
8 M 57 I None 60 — Yes RBBB 420
9 M 69 II Ischemic 23 Unlocated No RBBB 430
10 M 61 II Ischemic 32 Inferior Yes RBBB 320
EF  ejection fraction; FC  functional class; LBBB  left bundle branch block; MI  myocardial infarction; NYHA  New York Heart Association; RBBB  right bundle
branch block; VT  ventricular tachycardia.
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tered. The mean duration of the procedure was 112  43
min (range 56 to 180 min), and the mean fluoroscopy time
for the entire procedure was 43  17 min (range 18 to 78
min). Table 2 shows the main technical characteristics of
the procedures.
Target sites were identified by activation mapping, with
isolated mid-diastolic or presystolic potentials, during the
VT in 10 patients (example of tracings are reflected in Figs.
3 to 5). In the two cases with LBBB, the target site of
successful ablation was identified by isolated mid-diastolic
potentials. These potential sites were confirmed by entrain-
ment mapping in only four patients, because the stimulation
threshold was too high in the other patients (Fig. 5 depicts
an example of concealed entrainment). The mean activation
time of the epicardial electrogram preceding the QRS
complex of the surface ECG at the ablation site was 111 
36 ms (range 35 to 165 ms), an average of 27% of the
tachycardia cycle length.
Initial and long-term effects of ablation. The incessant
VT was effectively ablated from the epicardium in eight
patients, which gives a success rate of 80%. In two patients,
EpA failed to terminate the clinical tachycardia. In one
patient with a diagnosis of CAD, in which the epicardial
access failed to ablate the tachycardia, the VT was finally
ablated through standard endocardial access that had failed
previously. In the remaining patient with a diagnosis of
dilated cardiomyopathy, none of the ablations could termi-
nate the tachycardia, and urgent heart transplantation was
necessary because of hemodynamic instability and refractory
heart failure.
Primary success was achieved in eight patients in whom
VT was not inducible by programmed ventricular stimula-
tion 30 min after the procedure, using the same stimulation
protocol. In seven of these patients, the VT was successfully
ablated from the epicardium at the first attempt, including
the patient with anterior MI. In the remaining patient, two
epicardial sessions were necessary to ablate the tachycardia
due to early recurrence after an apparently effective first
procedure. The second session effectively ablated the tachy-
cardia without recurrences, and the post-procedure recovery
was not different from that of the other patients. Interest-
ingly, in both patients in whom endocardial access was not
attempted, EpA terminated the tachycardia effectively.
Together with the 10 incessant VTs, another seven
morphologies of VT were induced in six patients during the
procedure; four of them were hemodynamically stable and
targeted for ablation from the epicardium, as well, with
effective ablation in all of them, which gives a total success
rate of 85.7% (12 of 14 stable VTs). In four patients, two
VTs were ablated from the epicardium. The other poorly
tolerated VTs, although inducible after ablation, were not
targeted. The average number of applications per patient,
including those that failed to ablate the clinical VT, was 9
5 (range 2 to 17; median 8). During EpA, the energy
delivered had a mean power of 42 17 W (range 16 to 70 W)
and a mean temperature of 60  5°C (range 50 to 65°C).
No patient was lost to follow-up. All patients were
followed for at least two months, with a mean of 18  18
months (range 2 to 46 months). After ablation, oral amio-
darone was continued in three patients (33%). After dis-
charge, arrhythmia recurrence occurred in 1 (10%) of 10
patients while on amiodarone (Patient #1). It occurred two
years after the EpA, and the morphology and rate of the
tachycardia were completely different. He was referred again
for electrophysiologic study and the VT was successfully
ablated from the endocardial site, in a different location
from the previous one. After discharge, no patient had any
episode of syncope. All patients were alive at the end of
follow-up. Only two patients were readmitted to the hos-
pital. In one case (Patient #1), the reasons were VT
recurrence and ablation and heart failure decompensation.
In the other case (Patient #3), the reasons were heart
transplantation evaluation and biopsies.
Complications. The pericardial space was reached and the
catheter was freely moved in all patients, despite the
presence of transmural MI in seven patients (including four
cases of ventricular aneurysm) and one episode of acute
pericarditis, occurring two months before the procedure in
Patient #8. All RF applications were delivered in the left
Table 2. Technical Characteristics of Epicardial Ablation Procedures
Patient
No.
Procedure
Time (min)
X-Ray Time
(min)
Application
Time (s)
No. of
Applications
Energy
(W)
Catheter
(mm)
Maximum
Temperature
(°C) Result
1 150 65 256 7 40 8 63 Effective
2 157 77 120 2 26 4 65 Effective
3 120 42 358 15 50 8 60 Not effective
4 105 35 250 6 50 4 65 Effective
5 60 42 72 2 70 4 63 Effective
6 120 35 196 9 50 8 50 Not effective
7 180 36 271 7 20 4 60 Effective
8 115 40 718 13 16 4 65 Effective
9 56 35 346 11 50 4 54 Effective
10 59 18 206 4 50 4 60 Effective
Mean  SD 112  43 43  17 279  178 9  5 42  17 60  5 8/10
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ventricle. In none of them was a major coronary vessel
located near the application site. One patient had a calcified
apical aneurysm, and the catheter was positioned near its
base (Fig. 2).
No significant complications were observed. Two patients
had thoracic pain for three days after the procedure, which
needed analgesia with acetaminophen. The control echo-
cardiogram did not show significant pericardial effusion, and
cardiac enzymes were not significantly raised. Five patients
were in heart failure during the procedure. In four of them
with effective ablation, the hemodynamic state compensated
immediately after the ablation. The fifth patient underwent
urgent heart transplantation. No heart failure decompensa-
tion was observed immediately after the procedure, nor in
the following days. Moreover, the readmission of Patient #1
occurred one year later and was not related to the ablation.
DISCUSSION
Endocardial ablation of VT is often more difficult than
ablation of supraventricular tachycardia (SVT) and contin-
ues to be a challenging procedure. With the former, the
reported rates of success, ranging from 45% to75%, are
clearly lower than those for SVT, and furthermore, ablation
of VT has higher rates of recurrence (13–16). The presence
of critical parts of the VT circuit in the epicardium far away
from the endocardium has been suggested as one of the
reasons for these unsatisfactory results. In fact, it has been
Figure 3. (Top to bottom) 12-lead surface electrocardiograms and two electrograms from the endocardium and epicardium. The signal from the
endocardium shows a split potential. Ablation at this site was unsuccessful. From the epicardium, the electrical signal was discrete and had a similar
precocity. At this site, ablation was effective.
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reported that some VTs can be eliminated only by therapy
applied to intramural or epicardial sites, implying a noncrit-
ical role of the endocardium in such tachycardias (17). This
entails two problems: 1) how to locate these circuits; and 2)
how to ablate them.
Initial reports. Epicardial ablation was first performed
through open-chest heart surgery (5,6). The initial attempts
of EpA in the surgical suite were performed through the
coronary veins. Nevertheless, the technique has several limits.
The proximity of the coronary arteries has raised major
concerns; moreover, this procedure is limited by the veins’
anatomy and localization of the tachycardia circuit (7,18).
In 1996, Sosa et al. (8–11) introduced a new method to
perform both epicardial mapping in the electrophysiology
laboratory and posterior EpA. The results reported were
impressive because of the simplicity and effectiveness of the
technique. Initially, the procedure (previously described)
was used in patients with Chagas’ disease in South America,
exceptional in other countries (19,20). Afterward, it was
applied in the treatment of VTs in patients with chronic,
inferior MI (11). However, there is still a lack of informa-
tion on the risk of complications and efficacy in other
profiles of patients.
The present study confirms the feasibility, efficacy, and
safety of epicardial RF ablation in a nonselected population
of patients with incessant VT refractory to standard EdA.
Study population. We performed EpA in patients who
presented with incessant VT, in whom pharmacologic and
EdA have failed anteriorly. All but one of the patients
included in our series presented with a low ejection fraction.
Besides, three patients (33%) were diagnosed with multives-
sel disease. Finally, in four cases, a ventricular aneurysm was
identified. These characteristics are different from those of
the series reported by Sosa et al. (11) and similar to most
published series of EdA of VT (13–16).
Interestingly, in our patients, the MI was mainly located
in the inferoposterior wall. This is in accordance with
previous reports in which re-entrant circuits present in the
epicardium were more common in inferior wall infarction
(6,21).
Technical aspects and efficacy of epicardial access.
Despite the initial concerns of pericardial puncture in a dry
or normal pericardial space, it was possible to enter into this
space in all patients. Although most of them had a trans-
mural infarction, no anatomic obstacles inside the pericar-
dial sac were found to move the ablation catheter freely up
Figure 4. (Top to bottom) 12-lead surface electrocardiograms, endocardial signals from the right ventricle, and epicardial signals from the left ventricle
corresponding to two different ventricular tachycardias in the same patient. (Left) Epicardial signals show fractionated electrograms of high voltage present
during the diastole preceding the QRS complex. (Right) Epicardium signals show an isolated diastolic potential followed by a fractionated electrogram
preceding the QRS complex. In these sites, radiofrequency ablation effectively terminated the tachycardia depicted in the 12-lead electrocardiogram.
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to the appropriate position. It was possible even in patients
with a ventricular aneurysm, as well as in the patient with a
previous acute pericarditis. Furthermore, the stability and
contact of the catheter tip were good, accordingly with the
absence of cardiac structures interfering with it. It is possible
that this might have been different if the patient had been
previously submitted to heart surgery.
During tachycardia, we used a standard mapping ap-
proach with the detection of diastolic potentials in all the
cases and performance of entrainment mapping in four
patients (Fig. 4). This represents a standard approach to VT
in this case from the epicardium.
The duration of the procedure, fluoroscopy time, number
of applications, as well as the rest of the technical charac-
teristics of the ablation in terms of energy and temperature,
were similar to those published previously for EdA and the
results reported by Sosa et al. (11) and others (13–16).
With this approach, we successfully ablated the clinical,
incessant VT in 80% of cases. These results reveal how EpA
of VTs could be an effective complement to EdA and the
first choice for those patients with contraindications to
endocardial access. The combination of EdA and EpA may
improve the success rates of VT ablation. Further studies are
required in a wider spectrum of patients to demonstrate that
VT ablation with both approaches, in a stepwise fashion,
would increase the effectiveness of the procedure.
Safety. Several concerning issues have been raised in EpA.
The potential for tamponade and perforation of the heart,
risk of coronary occlusion due to RF application in prox-
imity to coronary vessels, or mediastinitis and other com-
plications of extravascular radiocontrast material have lim-
ited the utilization of this technique.
It is certain that there is a risk of pericardial effusion
caused by bleeding from the thoracic wall, coronary arteries,
or myocardial puncture. This could be higher with EpA
than with pericardiocentesis, as the former attempts to enter
in a virtual pericardial sac without a previous effusion.
Advancing the needle tip with small contrast infusions
could partially prevent this. In the series reported by Sosa et
al. (11), accidental right ventricular perforation occurred in
four patients of a total of 53 EpA procedures, even though
hemopericardium drainage was necessary only in three
patients in whom a small quantity (50 ml) was drained. In
the present study, we did not detect any pericardial effusion
either immediately after the procedure or on the day of
hospital discharge.
Figure 5. (Top to bottom) 12-lead surface electrocardiogram, endocardial signals from the right ventricle, and epicardial signals from the left ventricle. The
cycle length of the ventricular tachycardia was 510 ms. Pacing from the epicardium shows concealed entrainment and a return cycle identical to the
tachycardia cycle length. Ablation was effective at this site.
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All the manipulation maneuvers inside the pericardium
may also cause an inflammatory response in the days after
the procedure. In the present series, only two patients
presented with thoracic pain for three days afterward. No
other pericardial complications were found.
Additionally, the potential for coronary lesions, MI, and
further deterioration of heart function represents a great
concern. The precise relationship between the ablation
catheter tip and the coronary arteries is very difficult to
define. Furthermore, no safety distance has been estab-
lished. On the other hand, applications in infarct-related
areas have more chance to be near occluded or previously
severely damaged arteries, as it has been already said (19).
Moreover, voluntary damage in the coronary arteries has
been used as an option in some patients with incessant or
recurrent VT, using transcoronary chemical ablation (22–
24). Even assuming that a coronary lesion can be caused, the
risk must be balanced with the benefits in the different
populations. Our patients were in a situation (incessant VT)
in which we thought that the risk of complications had to be
assumed and so the patients were informed. Finally, none of
our patients had ischemic accidents, which reinforces the
idea of the safety of the procedure.
CONCLUSIONS
In patients with incessant VT not controlled with pharma-
cologic therapy or by standard EdA, the EpA was very
effective and no severe complications occurred. This tech-
nique should be considered as an alternative for these
patients who are at very high risk. Further studies are
warranted to define the usefulness of epicardial access for
VT ablation.
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